There were two tumors in one animal from your DSS + vehicle (PEG400) control group. 0.4 tumors per animal in the AOM + DSS + ABC294640 (50 mg/kg) group. Importantly, with ABC294640, there were no observed toxic Rabbit polyclonal to PAI-3 side effects. To explore mechanisms, we isolated cells from the colon (CD45, representing primarily colon epithelial cells) and (CD45+, representing primarily colon inflammatory cells) then measured known targets of SK that control cell survival. Results are consistent with the hypothesis that this inhibition of SK activity by our novel SK inhibitor Buthionine Sulphoximine modulates important pathways involved in cell survival and may be a viable treatment strategy for the chemoprevention colitis-driven colon cancer. == Introduction == Inflammatory bowel disease (IBD) is usually a group of disorders characterized by pathological inflammation of the lower intestine. Crohns Disease and Ulcerative Colitis are the most common forms. The roles of immune cells and inflammatory cytokines in the pathogenesis of IBD are well established. Activation of immune responses in IBD results in the local influx of mast cells, monocytes, macrophages and neutrophils, which produces the clinical manifestations of the diseases (1). This is accompanied by dramatic raises in tumor necrosis factor-alpha (TNF) (2), which has a main role in mediating both experimental and clinical IBD. Additionally, IBD is usually a high colon cancer risk disease. Cancers appear to arise from genetic alterations in cancer-related genes (oncogenes and suppressor genes), as well as an overall loss of genomic stability. The etiological and tissue microenvironment factors that spawn colitis and progression to colon cancer are still unclear. So far, this has resulted in limited success for prevention of colitis and colon cancer associated with this disease, and new molecular targets for their prevention and/or treatment are needed. The mechanisms and effects of the sphingolipid interconversion have been the subjects of a growing body of scientific investigation. Sphingomyelin is a structural component of cellular membranes and is a precursor for the potent bioactive lipids ceramide and sphingosine 1-phosphate (S1P). A ceramide/S1P rheostat has been hypothesized to determine the fate of the cell, such that the relative cellular concentrations of ceramide and S1P determine whether a cell proliferates or undergoes apoptosis. Ceramide is usually produced by the hydrolysis of sphingomyelin in response to inflammatory stresses, including TNF, which is a important target in colitis (3,4). Ceramide induces apoptosis in tumor cells (5) and can be further hydrolyzed by the action of ceramidase to produce sphingosine (Sph). Sph is usually then rapidly phosphorylated by sphingosine kinase (SK) to produce S1P. Ceramidase and SK are also activated by cytokines and growth factors, leading to rapid increases in the intracellular levels of S1P and depletion of ceramide levels. This promotes cell proliferation and inhibits apoptosis, and deregulation of apoptosis in phagocytes is an important component of the chronic inflammatory state in IBDs. S1P also has several important effects on immune function. Platelets, monocytes and mast cells secrete S1P upon activation, promoting inflammatory cascades in damaged tissue (6). SK activation is required for the signaling responses since the ability of TNF to induce adhesion molecule expression via activation of nuclear factor-kappaB is usually mimicked by S1P and blocked by the SK inhibitor dimethylsphingosine (3). Similarly, S1P mimics the ability of TNF to induce COX-2 expression and prostaglandin E2 synthesis; and knock down of SK blocks these responses to TNF but not S1P (7). In intestinal endothelial cells, S1P activates nuclear factor-kappaB thereby inducing the expression of adhesion molecules, COX-2 resulting in prostaglandin E2 synthesis and nitric oxide synthase generating nitric oxide. With each other, these chemoattractants and the adhesion molecules promote neutrophil infiltration into the mucosa. SK has been directly demonstrated to play a significant role in the recruitment and function of these cells (8,9). At the same time, S1P activates neutrophils resulting in the release Buthionine Sulphoximine of oxygen free radicals that further inflame and eliminate epithelial tissues. Overall, it is obvious that S1P is critical in inflammation, making SK an excellent target for the development of new anti-inflammatory/chemopreventive drugs. Here, we confirm that a novel small molecule SK inhibitor [ABC294640, (10)] can prevent colitis (11) and show for the first time that it also suppresses colon cancer associated with colitis in a doseresponse manner. == Buthionine Sulphoximine Materials and methods == == Animals == All mice (C57BL/6) used were.